Inmune Bio (INMB) Net Cash Flow (2018 - 2026)
Inmune Bio (INMB) posted Net Cash Flow of -$3.4 million for Q1 2026, down 10.63% sequentially from -$3.1 million in Q4 2025, and down 119.55% YoY from $17.4 million in Q1 2025.
Inmune Bio (INMB) Net Cash Flow (2018 - 2026) Analysis & Trends
Inmune Bio has reported Net Cash Flow for 9 years, with the latest figure at -$3.4 million in Q1 2026.
- Quarterly Net Cash Flow fell 119.55% year-over-year to -$3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (up 141.74% YoY) and the FY2025 annual result came in at $4.0 million, up 126.14% from the prior year.
- Net Cash Flow slipped to -$3.4 million in Q1 2026 per INMB's latest filing, from -$3.1 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $14.9 million in Q2 2025 and troughed at -$13.1 million in Q4 2024.
- A 5-year average of -$3.0 million and a median of -$3.4 million in 2026 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 261.03% in 2024, down 774.32% in 2024.
- Over 5 years, Net Cash Flow stood at -$5.7 million in 2022, then retreated by 3.97% to -$5.9 million in 2023, then plunged by 121.75% to -$13.1 million in 2024, then surged by 76.57% to -$3.1 million in 2025, then dropped by 10.63% to -$3.4 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$3.4 million, -$3.1 million, and -$5.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.07 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.92 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.86 Bn | 53.72 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 27.88 Bn | 9.49 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 225.59 Mn |
| 10 | Inmune Bio | 61.85 Mn | 43.44 Mn | - | -3.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.20 Mn |
| Jun 30, 2026 | -3.20 Mn |
| Mar 31, 2026 | -3.40 Mn |
| Mar 31, 2026 | -3.40 Mn |
| Dec 31, 2025 | -3.08 Mn |
| Dec 31, 2025 | -3.08 Mn |
| Sep 30, 2025 | -5.59 Mn |
| Sep 30, 2025 | -5.59 Mn |
| Jun 30, 2025 | 14.90 Mn |
| Jun 30, 2025 | 14.90 Mn |
| Mar 31, 2025 | -1.55 Mn |
| Mar 31, 2025 | -1.55 Mn |
| Dec 31, 2024 | -13.13 Mn |
| Dec 31, 2024 | -13.13 Mn |
| Sep 30, 2024 | 2.81 Mn |
| Sep 30, 2024 | 2.81 Mn |
| Jun 30, 2024 | 5.11 Mn |
| Jun 30, 2024 | 5.11 Mn |
| Mar 31, 2024 | -9.98 Mn |
| Mar 31, 2024 | -9.98 Mn |